L-701324

{{Drugbox | verifiedfields = changed | verifiedrevid = 477318295 | IUPAC_name = 7-Chloro-5-[[4-[[4-(2-methylphenyl)piperazin-1-yl]methyl]phenyl]methyl]-3H-1,2,4-triazolo[4,3-b]pyridazine | image = L-701324.svg | image_size = 200px | image_alt = Chemical structure of L-701324 | width = | alt = | CAS_number = 142326-59-8 | PubChem = 5311275 | ChemSpiderID = 4470900 | UNII = 0T3F4Y0X0W | KEGG = D08213 | ChEMBL = 2103870 | C=24 | H=25 | Cl=1 | N=6 | smiles = CC1=CC=CC=C1N2CCN(CC2)CC3=CC=C(C=C3)CN4C5=NN=CC=C5C=C4Cl }}

L-701324 is a chemical compound that acts as a selective antagonist of the NMDA receptor, specifically targeting the glycine site of the receptor. It is primarily used in scientific research to study the role of the NMDA receptor in various neurological processes and disorders.

Chemical Structure

Chemical structure of L-701324

L-701324 is a triazolopyridazine derivative with the IUPAC name 7-Chloro-5-[[4-[[4-(2-methylphenyl)piperazin-1-yl]methyl]phenyl]methyl]-3H-1,2,4-triazolo[4,3-b]pyridazine. The compound features a chloro-substituted triazolopyridazine core, which is linked to a piperazine moiety through a phenylmethyl bridge.

Pharmacology

L-701324 functions as a competitive antagonist at the glycine site of the NMDA receptor. The NMDA receptor is a type of glutamate receptor that plays a crucial role in synaptic plasticity, memory formation, and neurodevelopment. By inhibiting the glycine site, L-701324 can modulate the activity of the NMDA receptor, making it a valuable tool for investigating the receptor's function in the central nervous system.

Research Applications

L-701324 is utilized in various research settings to explore the involvement of NMDA receptors in neurological conditions such as schizophrenia, Alzheimer's disease, and epilepsy. Its ability to selectively block the glycine site allows researchers to dissect the contributions of this site to the overall function of the NMDA receptor.

Schizophrenia

In studies of schizophrenia, L-701324 has been used to model the effects of NMDA receptor hypofunction, a condition thought to be associated with the disorder. By blocking the glycine site, researchers can simulate the reduced NMDA receptor activity observed in schizophrenia, providing insights into potential therapeutic targets.

Neuroprotection

L-701324 has also been investigated for its neuroprotective properties. By modulating NMDA receptor activity, it may help prevent excitotoxicity, a process where excessive glutamate activity leads to neuronal damage and cell death. This property is of interest in conditions such as stroke and traumatic brain injury.

Safety and Toxicology

As a research chemical, L-701324 is not intended for human use, and its safety profile in humans is not well-established. In laboratory settings, it is handled with care to avoid exposure, and its effects are studied in controlled environments.

Related Pages

• NMDA receptor
• Glycine receptor
• Glutamate receptor
• Schizophrenia
• Neuroprotection